Specifically, even if it is a rare variant (ExAc allele frequency = 0.7%) recently described as associated with an increased risk of developing breast and ovarian cancers [28], the heterozygous stop gain of BRCA2 (p.K3326X) is considered as “benign” in ClinVar. Here, BRCA2 is linked to ovarian carcinoma.